集友股份(603429.SH):董事長於8月11日通過大宗交易減持257.79萬股
格隆匯 8 月 11日丨集友股份(603429.SH)公佈,2020年8月11日公司收到控股股東、董事長徐善水出具的《關於股東權益變動暨股份減持進展情況告知函》,徐善水於2020年8月11日通過上海證券交易所大宗交易系統減持公司股票257.79萬股,約佔公司2020年8月11日總股本380,238,957股的0.68%。
自此,自2017年1月24日公司上市以來,徐善水權益變動比例(含因公司實施非公開發行新股以及實施股權激勵被動稀釋的股權比例)累計達到5%,徐善水同時出具了《簡式權益報告書》。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.